tbuckley/cabot-search huggingface dataset:
Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: A retrospective study in Spanish population
Authors: S. Perez Ramirez, M. del Monte-Millán, S. López-Tarruella, I. Márquez-Rodas, Y. Jerez, F. Lobo Samper, Y. Izarzugaza Peron, N. Martínez Jañez, J.A. García-Saenz, F. Moreno Antón, P. Zamora Auñón, M. Arroyo Yustos, M.Á. Lara Álvarez, E.M. Ciruelos Gil, L. Manso Sánchez, M.J. Echarri González, J.A. Guerra Martínez, C. Jara Sánchez, V. Valentín Maganto, M. Martin Jimenez
Journal: Annals of Oncology (2017)
Abstract 305: Carvacrol Attenuates Diabetic Cardiomyopathy by Enhancing PI3K/AKT Pathway in STZ-induced Type 1 Diabetic C57BL/6J Mice
Authors: Ning Hou, Yunpei Mai, Wenliang Chen, Faqian Li, Jiandong Luo
Journal: Circulation Research (2016)

Background: Carvacrol (CAR), a monoterpenic phenol that occurs in many essential oils of the family Labiatae including Origanum , Satureja , Thymbra , Thymus , and Corydothymus species, possess a wide variety of pharmacological properties including antioxidant and anti-inflammatory potential. This present study was designed to investigate the cardiac protective effect of CAR on diabetic cardiomyopathy in STZ-induced type 1 diabetic mice and explore its potential molecular mechanism. Methods: Type 1 diabetes was induced by the intraperitoneal injection of streptozocin (STZ) to male mice at dose of 45 mg/kg body weight (BW). The diabetic animals were divided into three groups containing eight in each: Group I diabetes, Group II and II injected with CAR at 10 and 20 mg/kg BW respectively once daily for 6 weeks. Age matched male C57 mice were used as normal controls. The plasma concentrations of glucose, total cholesterol (TC) and triglycerides (TG) levels were enzymatically determined using commercial kits. The cardiac function was measured by echocardiography. Protein levels of p-PDK1/t-PDK1, p-AKT/t-AKT, p-GSKα/β/t-GSKα/β were detected by Western blotting. Results: STZ-induced C57BL/6J diabetic mice showed an elevation in serum glucose, TG and TC level. Compared to diabetic mice, administration of CAR resulted in significant decrease ( P &lt;0.05) in plasma glucose level in a dose dependent manner, but did not attenuate elevation in TG and TC levels. The abnormal diastolic function in type 1 diabetic mice was significantly reversed by CAR administration. Furthermore, western blotting showed that the expression of p-PDK1, p-AKT and p-GSKα/β were lower in diabetic hearts than C57 hearts while total PDK1, AKT and GSK α/β protein levels were no difference among groups. CAR administration attenuated these decreases in protein phosphorylation. These findings indicate that the impaired PI3K/AKT pathway induced by STZ in diabetic heart can be restored by CAR. Conclusion: Carvacrol has antidiabetic property and can be potentially used to prevent hyperglycemia and diabetic cardiomyopathy.
The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
Authors: C. Dellepiane, M. Lambertini, V. Fontana, F. Poggio, E. Blondeaux, B. Conte, A. D'Alonzo, M. Vaglica, C. Bighin, G. Iacono, A. Abate, S. Pastorino, M.C. Pescio, P. Anserini, L. Del Mastro
Journal: Annals of Oncology (2017)
Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 sudy in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
Authors: M. Tahara, M.S. Brose, L. Wirth, T. Suzuki, K. Fujino, N. Batty, C. Dutcus, A. Gianoukakis
Journal: Annals of Oncology (2017)
Production of Malignancy in Vitro. VII. Metabolism and Biotin Vitamer Content of Tumors Produced
Authors: Dean Burk, Wilton R. Earle, Richard J. Winzler, Doris F. MacNeary, Marie Hesselbach, Emma Shelton, Edward L. Schilling
Journal: JNCI Journal of the National Cancer Institute (1944)

Production of Malignancy in Vitro. VII. Metabolism and Biotin Vitamer Content of Tumors Produced Get access Dean Burk, Dean Burk senior chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Wilton R. Earle, Wilton R. Earle senior cytologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard J. Winzler, Richard J. Winzler research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Doris F. MacNeary, Doris F. MacNeary National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Marie Hesselbach, Marie Hesselbach National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Emma Shelton, Emma Shelton National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Edward L. Schilling Edward L. Schilling National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 4, February 1944, Pages 363–372, https://doi.org/10.1093/jnci/4.4.363 Published: 01 February 1944
Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): the open-label, single-arm, single-center, phase 2, CaboPen trial
Authors: A. Necchi, L. Mariani, M. Colecchia, P. Giannatempo, D. Raggi, G. Calareso, N. Nicolai, M. Catanzaro, T. Torelli, F. Perrone, R. Salvioni
Journal: Annals of Oncology (2017)
The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas
Authors: V. Boni, J. Garcia-Corbacho, J. Feliu, J. Wydmanski, Z. Horvath, I. Bondarenko, B. Irving, M. Will, E.G.E. de Vries, F. Thistlethwaite
Journal: Annals of Oncology (2017)
SHP-1 agonist SC-43 enhanced the anti-tumor effect of docetaxel through suppressing p-STAT3 in triple negative breast cancer cells
Authors: K-F. Chen, C-Y. Liu, T-I. Chao, P-Y. Chu, T-T. Huang, W-L. Wang, C-H. Lee, K-Y. Lau, W-C. Tsao, C-W. Shiau, L-M. Tseng
Journal: Annals of Oncology (2017)
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
Authors: Ludovic Barault, Alessio Amatu, Giulia Siravegna, Agostino Ponzetti, Sebastian Moran, Andrea Cassingena, Benedetta Mussolin, Chiara Falcomatà, Alexandra M Binder, Carmen Cristiano, Daniele Oddo, Simonetta Guarrera, Carlotta Cancelliere, Sara Bustreo, Katia Bencardino, Sean Maden, Alice Vanzati, Patrizia Zavattari, Giuseppe Matullo, Mauro Truini, William M Grady, Patrizia Racca, Karin B Michels, Salvatore Siena, Manel Esteller, Alberto Bardelli, Andrea Sartore-Bianchi, Federica Di Nicolantonio
Journal: Gut (2017)

Objective Mutations in cell-free circulating DNA (cfDNA) have been studied for tracking disease relapse in colorectal cancer (CRC). This approach requires personalised assay design due to the lack of universally mutated genes. In contrast, early methylation alterations are restricted to defined genomic loci allowing comprehensive assay design for population studies. Our objective was to identify cancer-specific methylated biomarkers which could be measured longitudinally in cfDNA (liquid biopsy) to monitor therapeutic outcome in patients with metastatic CRC (mCRC). Design Genome-wide methylation microarrays of CRC cell lines (n=149) identified five cancer-specific methylated loci ( EYA4 , GRIA4 , ITGA4 , MAP3K14-AS1, MSC ). Digital PCR assays were employed to measure methylation of these genes in tumour tissue DNA (n=82) and cfDNA from patients with mCRC (n=182). Plasma longitudinal assessment was performed in a patient subset treated with chemotherapy or targeted therapy. Results Methylation in at least one marker was detected in all tumour tissue samples and in 156 mCRC patient cfDNA samples (85.7%). Plasma marker prevalence was 71.4% for EYA4 , 68.5% for GRIA4 , 69.7% for ITGA4 , 69.1% for MAP3K14-AS1% and 65.1% for MSC . Dynamics of methylation markers was not affected by treatment type and correlated with objective tumour response and progression-free survival. Conclusion This five-gene methylation panel can be used to circumvent the absence of patient-specific mutations for monitoring tumour burden dynamics in liquid biopsy under different therapeutic regimens. This method might be proposed for assessing pharmacodynamics in clinical trials or when conventional imaging has limitations.
Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
Authors: R. Ferrara, C. Caramella, M. Texier, C. Audigier Valette, L. Tessonnier, L. Mezquita, J. Lahmar, J. Mazieres, G. Zalcman, S. Brosseau, V. Westeel, S. Le Moulec, L. Leroy, B. Duchemann, R. Veillon, D. Planchard, M.-E. Boucher, S. Koscielny, J.-C. Soria, B. Besse
Journal: Annals of Oncology (2017)
Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial
Authors: M. Teufel, H. Seidel, K. Köchert, G. Meinhardt, R.S. Finn, J.M. Llovet, J. Bruix
Journal: Annals of Oncology (2017)
Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
Authors: Seongjoon Park, Jae-Lyun Lee, Inkeun Park, Kwonoh Park, Yongchel Ahn, Jin-Hee Ahn, Dae Ho Lee, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
Journal: Journal of Clinical Oncology (2012)

e15080 Background: Currently, sunitinib has been recommended as the primary treatment in the patients with metastatic renal cell carcinoma (mRCC) among the vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI). However, there are no published clinical data that compared directly the efficacy of targeted agents in the first line setting, and first-line treatment in mRCC patients is yet to be determined. Methods: To compare the efficacy and toxicities between sorafenib and sunitinb, clinical database was used to identify all patients with mRCC treated with VEGF TKIs in Asan Medical Center from April 2005 to March 2011. Among 304 patients, we identified 49 and 220 patients who were treated first with sorafenib and sunitinib, respectively. Results: The patients in the sorafenib group were older than those in the sunitinib group (62 vs 56.5 years, p=0.019). Disease control rate (DCR) of 82% was achieved in both groups. After a median follow-up duration of 49 months, progression free survival (PFS) and overall survival (OS) were not significantly different (sorafenib vs sunitinib, PFS; 8.6 months vs 9.9 months, p=0.948, OS; 25.7 months and 22.6 months, p=0.774). The patients treated with sorafenib have required dose reduction due to toxicities less frequently than those treated with sunitinib (37% vs 54%, p=0.034). Hematologic toxicities of grade 3 or 4 were more common in sunitinib group (4.2% vs 44.6%, p&lt;0.001), and also was grade 3 or 4 hypertension, although it was not statistically significant (4.2% vs 13.7%, p=0.06). Age (&gt; 60 years), duration from diagnosis to treatment (less than 1 year), Anemia, Neutrophilia, thorombocytosis, bone and liver metastases were independent prognostic factors affecting OS. Multivariate analysis also showed first-line VEGF TKI did not affect OS [hazard ratio (HR, sorafenib vs sunitinib) = 0.94, p=0.774]. Conclusions: Sorafenib showed comparable efficacy to sunitinb and demonstrated superiority in toxicities in the treatment of mRCC patients.
Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)
Authors: T. Lin, L. Hydutsky, H. Parros, S. Murphy, H. Pei, A. Londhe, J. Ukropec, M. Qi, Y. Lutska, M. Sharma
Journal: Annals of Oncology (2017)
A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection
Authors: P-J. Chen, P-H. Lee, K-H. Han, J. Fan, T.T. Cheung, R-H. Hu, S.W. Paik, W-C. Lee, G-Y. Chau, L-B. Jeng, H.J. Wang, J.Y. Choi, C-L. Chen, M. Cho, M-C. Ho, C-C. Wu, K.S. Lee, Y. Mao, F-C. Hu, K-L. Lai
Journal: Annals of Oncology (2017)
1,3,5 s-triazine containing analogues a prime Src family inhibitor: Design synthesis docking, anticarcinoma and angiogenic inhibition efficacy on cancer grafted CAM
Authors: P. Pathak, A. Balkrishna, P.K. Shukla, V. Kumar, A. Kumar, A.K. Singh, A. Verma
Journal: Annals of Oncology (2017)
Falls and disability among female cancer survivors
Authors: Lara C. Pullen
Journal: CA A Cancer Journal for Clinicians (2017)

Key Points Approximately one‐half of women have symptoms of CIPN 6 years after treatment. Women with persistent CIPN symptoms were found to have poorer physical functioning, more disability, and nearly twice the rate of falls as asymptomatic women. Women with neuropathy, pain, and weakness frequently lose their ability to perform even basic exercises correctly.
Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
Authors: T. Meniawy, G. Richardson, A. Townsend, J. Desai, H. Gan, M. Friedlander, L. Horvath, M.B. Jameson, S. Sandhu, Z. Wu, Z. Qin, K. Kang, B. Markman
Journal: Annals of Oncology (2017)
Peanut allergy
Authors: R. Clifford
Journal: BMJ (1996)

young and older children.During 1990-6 sensi- tisation (¢3+, wheal diameter approximately 3 mm) to peanut was found in 1601 infants and children, and sensitisation to a tree nut (almond, brazil, cashew, hazelnut, or walnut) in 590; 491 were sensitised to both (fig 1).This represents a combined prevalence of sensitisation of at least 0.2%.Sensitisation occurred early: 920 children aged under 24 months were sensitised to peanut and 270 to a tree nut.100-80-g0601 et 40 e go 3+ 20-11112 -1+ =0 0 ~~\ ~~F ig 1-Maximum recorded sensitisation score for each child tested, 1990-6 (n = 4078).Sensitisation to nut extracts (Hollister-Stier, USA) was scored by com- paring diameter of skin wheal in reaction to extract with that of wheal in reaction to histamine 1 mg/ml (on average 3 mm): 1+ if less than half diameter of hista- mine wheal, 2+ if equal to half diameter, 3+ if equal to diameter, 4+ if equal to twice diameter, and 5+ if greater than twice diameter
A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.
Authors: Hugo Valencia, Herbert B. Newton, Erinn Hade, Douglas Weston Sborov, Robert Cavaliere, Ming Poi, Mitch Phelps, Jiang Wang, Christopher C Coss, Soun Khountham, Paul Monk, Thomas Olencki, Charles L Shapiro, Richard Piekarz, Craig C. Hofmeister, Michael R. Grever, D. Bradley Welling, Amir Mortazavi
Journal: Journal of Clinical Oncology (2016)

2558 Background: We have shown that AR-42, an oral pan-histone deacetylase inhibitor, has clinical activity in some hematologic malignancies and preclinical activity in certain solid tumors, including neurofibromatosis type 2 (NF2)-associated meningiomas and schwannomas. Therefore, this phase 1 trial was initiated to investigate the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) in patients with advanced solid tumors. Methods: This is a single-agent, standard 3+3, phase 1 dose-escalation study, with an additional expansion cohort at the MTD; mainly enrolling patients with malignancies of interest, based on our preclinical data. AR-42 was given in a 28-day cycle (3 times weekly, 3-week on, 1-week off). Plasma samples were collected following the first dose to assess pharmacokinetics in each patient. Results: Seventeen patients were enrolled in this study. Two patients were replaced and 15 patients were evaluable for safety and response. Patients had a median age of 49 (range: 20-80) and were heavily pretreated (41% had 3 prior regimens). Primary tumor sites included NF2-associated tumors (n = 5), meningioma (n = 2), transitional cell carcinoma (n = 3), breast cancer (n = 2), and other (n = 5). The MTD was defined as 60 mg and the DLTs were two grade 3 thrombocytopenias; and one grade 4 psychiatric disorder, possibly related to AR-42 (at 80 mg). The most common toxicities were fatigue, cytopenias, electrolytes imbalance, nausea/vomiting and elevated creatinine, which were manageable. The best response was stable disease (53%, 8/15 patients) with a median progression free survival (mPFS) of 4.4 months (95% CI: 1.2-13.9). Interestingly, for NF2 and meningioma patients, the mPFS was 13.9 months. Individual plasma AR-42 Cmax and AUC0-24hr values ranged from 0.54 to 3.25 μM and 4.93 to 27.6 μM*Hr across the dose range, respectively. Conclusions: Single-agent oral AR-42 is well tolerated and associated with modest anti-tumor activity in patients with advanced solid tumors, especially those with NF2-asociated tumors and meningiomas. Pharmacokinetic data suggests active drug levels are achieved in plasma. In this study, the MTD is determined to be 60 mg, once daily, 3 times weekly, 3-week on and 1-week off. Clinical trial information: NCT01129193.
Efficacy and safety of trabectedin in an elderly patient subgroup (≥65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) from the Expanded Access Program (EAP)
Authors: R.L. Jones, R. Maki, S. Patel, G. Wang, C.R. Shin, R. Knoblauch, G.D.S. Demetri
Journal: Annals of Oncology (2017)
Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262–70
Authors: Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, Samuel D. Kaffenberger
Journal: European Urology (2017)
GW28-e0740 eHelp China, a randomised trial evaluating the effect of a smart phone-based patient support tool on treatment duration in patients prescribed rosuvastatin in China
Authors: Xin Du, M. Jornten Karlsson, Y. Xu, J. Guo, J. Li, X. Mei, L. Han, J. Wang, Z. Shen, A. Ryden, M. Ahlqvist, M. Sunden, B.W. Karlson, C. Ma
Journal: Journal of the American College of Cardiology (2017)
Un brote de tularemia de transmisión aérea en Francia, agosto de 2004
Authors: V Siret, D Barataud, M Prat, V Vaillant, S Ansart, A Le Coustumier, J Vaissaire, F Raffi, M Garré, I Capek
Journal: Eurosurveillance (2006)

Entre el 9 y el 12 de agosto de 2004 se identificaron 15 casos de tularemia tras una estancia en un molino trasformado en casa de huespedes, en Vendee, Francia. 
Se realizo una visita al molino, asi como encuestas descriptivas, de cohorte retrospectivo y ambientales. Las 39 personas que se habian hospedado en el molino entre el 24 de julio y el 11 de agosto fueron entrevistadas sobre sus sintomas y exposiciones (alimentarias, animales), y sus actividades de tiempo libre. 
Un caso se definio como una persona con fiebre y serologia positiva (seroconversion o aumento significativo del titulo de anticuerpos o titulo unico ≥ 40). Se busco Francisella tularensis por cultivo y PCR en el agua de beber del molino, en la lena, y en los animales domesticos. 
Fueron confirmados 15 (38%) casos de tularemia, de los cuales 12 (el 80%) presentaban una forma pulmonar. No fue hospitalizado ningun caso. 
La presencia en el molino durante la cena del 4 de agosto estaba fuertemente asociada con la enfermedad (pl10-8). Uno de los tres perros que estaban en el comedor en esa cena revelo positivo para F. tularensis. 
Los analisis ambientales fueron negativos. 
Estas investigaciones confirmaron la presencia de 15 casos agrupados de tularemia, infectados en la noche del 4 de agosto en un molino de Vendee, un area endemica para tularemia. Tambien mostraron que existen en Francia formas pulmonares no especificas y benignas. 
La forma pulmonar de la infeccion en los casos humanos y la serologia positiva del perro sugieren una contaminacion por inhalacion de particulas contaminadas procedentes del pelo del animal, diseminadas por el aire al sacudirse este.
Novo surto de triquinelose na região de Midi-Pyrénées em França, Setembro a Outubro de 1998
Authors: C Hemery, S Haeghebaert
Journal: Eurosurveillance (1999)

Em 6 de Outubro, foram notificados no departamento de saude regional da regiao de Midi-Pyrenees, onze casos de triquinelose ocorridos nos distritos de Haute-Garonne e Tarn, em Franca (1). Em todos os casos tinha sido ingerida carne de cavalo, comprada num talho em Toulouse e noutro em Castres. Foi efectuada uma investigacao epidemiologica, veterinaria e parasitologica, para avaliar a importância do surto e identificar o veiculo e a fonte da infeccao.
Effect of molecular mechanisms mediating bevacizumab (BEV) and vanucizumab (VAN) on gastrointestinal perforation: Use of artificial neural networks for integrated data analysis.
Authors: Jonathan Wagg, Oliver Krieter, Chia-Huey Ooi, Samuel Croset, Mathias Leddin, Raquel Valls, Jose Manuel Mas, Christophe Boetsch
Journal: Journal of Clinical Oncology (2017)

e15108 Background: VAN is a novel bispecific mAb targeting VEGF &amp; ANG-2. A randomized phase 2 study (McCAVE) investigating VAN &amp; BEV, each combined with chemotherapy (mFOLFOX-6), in 1L metastatic colorectal cancer patients was completed. Reported gastrointestinal perforation (GIP) events (including GI fistula &amp; abdominal abscess) in both arms (approx. 10%) exceeded those expected with BEV+CTx. The present work focused on identifying the explicit molecular pathways mediating VAN/BEV associated GIP. Methods: Clinical data from McCave (safety outcomes &amp; gene expression profiling) was integrated with data from other clinical/preclinical VAN/BEV studies. Machine learning was applied to the dataset to computationally infer GIP mechanisms. The methodology was constrained by relevant biological &amp; clinical knowledge. Literature reviews &amp; database queries mapped 194 unique proteins to 8 biological processes previously hypothesized to play a role in GIP. Identified proteins guided construction of a GIP protein interaction network which was transformed into an artificial neural network and was fitted to the dataset to predict molecular pathways/biological processes most likely linking VEGF-A and/or ANG-2 inhibition to GIP. Results: VAN/BEV were predicted to enhance GIP risk via 4 out of 8 previously suggested biological effects: (i) reduced GI mucosal integrity; (ii) impaired wound healing; (iii) inhibition of angiogenesis (iv) increased thromboembolic risk. The specific proteins &amp; associated interactions predicted to mediate these 4 effects were identified as solely VEGF-A inhibition driven. These effects may drive increased susceptibility to GIP triggered by secondary insults, e.g. preclinical ulcer &amp; intramural lesion. Candidate GIP biomarkers for monitoring these effects were identified, e.g., aPTT, citrulline &amp; I-FABP. Conclusions: The molecular pathways mediating GIP in VAN/BEV treated patients are likely driven by VEGF inhibition with no contribution from ANG-2 inhibition. It is proposed, that in addition to VAN/BEV, one or more secondary insults to the GI tract wall are required to drive perforation.
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice
Authors: S. Delaloge, P.F. Conte, S-A. Im, E. Senkus-Konefka, B. Xu, S.M. Domchek, N. Masuda, W. Li, N. Tung, A. Armstrong, W. Wu, C. Goessl, S. Runswick, M. Robson
Journal: Annals of Oncology (2017)